The Global Neuromodulation Devices Market Size is projected to grow at a CAGR of 10.6% during the forecast period from 2026 to 2034 | DelveInsight

DelveInsight's Neuromodulation Devices Market Insights Report 2034 provides the current and forecast market analysis, individual leading Neuromodulation Devices companies' market shares, challenges, Neuromodulation Devices Market Drivers, barriers, trends, and key market Neuromodulation Devices companies in the market.

To read more about the latest highlights related to the Neuromodulation Devices Market @ https://www.delveinsight.com/sample-request/neuromodulation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Neuromodulation Devices Market Report
• In January 2026, Boston Scientific Corp. progressed toward completing its previously announced acquisition of Nalu Medical, expanding its neuromodulation portfolio into peripheral nerve stimulation for chronic pain. Strategic significance: Broadens Boston Scientific's chronic-pain portfolio beyond spinal cord stimulation into peripheral nerve stimulation.
• In November 2025, LivaNova PLC announced that the U.S. Centers for Medicare & Medicaid Services assigned VNS Therapy to an upgraded New Technology Ambulatory Payment Classification, effective January 2026, improving hospital procedure economics. Strategic significance: Broadens patient access to VNS Therapy and strengthens LivaNova's reimbursement position in drug-resistant epilepsy.
• In October 2025, Boston Scientific Corp. entered a definitive agreement to acquire Nalu Medical, Inc. for an upfront cash payment of approximately USD 533 million, its third neuromodulation-related acquisition of 2025. Strategic significance: Adds differentiated peripheral nerve stimulation technology to Boston Scientific's chronic-pain portfolio.
• The Neuromodulation Devices market is estimated at USD 6.42 billion in 2025 and is projected to reach USD 15.85 billion by 2034. Growth is anchored in the rising global burden of chronic pain and neurological disorders, rapid adoption of closed-loop and AI-enabled stimulation platforms, and expanding regulatory approvals and reimbursement across major markets.
• The global Neuromodulation Devices market is growing at a CAGR of 10.6% during the forecast period from 2026 to 2034.
• The principal drivers are the rising global prevalence of chronic pain and failed back surgery syndrome; the growing burden of neurological and movement disorders, including Parkinson's disease and drug-resistant epilepsy; rapid advancement toward closed-loop and AI-enabled stimulation platforms; expanding regulatory approvals and reimbursement support; and active strategic investment and M&A activity among leading manufacturers.
• The leading Neuromodulation Devices Companies include Abbott Laboratories, Smith's Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC, Medtronic, Nevro Corp., and Stryker, among others.

To know more about why North America is leading the market growth in the Neuromodulation Devices Market, Get a snapshot @ https://www.delveinsight.com/sample-request/neuromodulation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Neuromodulation Devices Overview
Neuromodulation devices are medical devices that deliver targeted electrical, magnetic, or chemical stimulation to specific nerves or regions of the nervous system to modify abnormal neural activity and treat a variety of neurological, chronic pain, and psychiatric disorders. These devices help regulate nerve function without permanently altering the underlying anatomy, offering a minimally invasive or non-invasive therapeutic option for patients who do not respond adequately to conventional treatments.

Neuromodulation Devices Market Key Growth Drivers
• The rising global prevalence of chronic pain and failed back surgery syndrome is driving durable demand for spinal cord stimulation, reinforced by continued platform upgrades such as Nevro's HFX iQ and Medtronic's Inceptiv closed-loop rechargeable stimulator.
• The growing burden of neurological and movement disorders is expanding demand for deep brain and vagus nerve stimulation; the Parkinson's Foundation estimates around 1 million people are living with Parkinson's disease in the U.S., a figure projected to reach 1.2 million by 2030.
• Rapid technological advancement toward closed-loop, adaptive, and AI-enabled stimulation is improving outcomes and broadening adoption, exemplified by Medtronic's BrainSense Adaptive DBS system, which received FDA approval in February 2025 as the first closed-loop neuromodulation therapy for Parkinson's disease.
• Expanding regulatory approvals and reimbursement support are increasing patient access, including Medtronic's September 2025 FDA approval of the Altaviva tibial neuromodulation system for urge urinary incontinence and LivaNova's November 2025 CMS reimbursement upgrade for VNS Therapy under the 2026 Medicare Hospital Outpatient Prospective Payment System.
• Active strategic investment and M&A are consolidating and expanding neuromodulation capacity, including Boston Scientific's agreement to acquire Nalu Medical for approximately USD 533 million (announced October 2025) and Globus Medical's approximately USD 250 million acquisition of Nevro Corp. (announced February 2025).
• Growing physician and patient preference for device-based, non-pharmacological alternatives to opioid therapy, combined with rising government funding for neuromodulation research, is broadening the addressable patient population across pain and neurological indications.
• The convergence of technological innovation, expanding indications, rising disease burden, and reimbursement support is expected to sustain strong double-digit growth in the market through 2034.

Get a sneak peek at the Neuromodulation Devices Market Dynamics @ https://www.delveinsight.com/sample-request/neuromodulation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Neuromodulation Devices Market Segment Analysis
The Neuromodulation Devices by Device Type (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, and Others), Application (Pain Management, Urinary & Faecal Incontinence, Neurological Disorders, Respiratory Disorders, and Others), Type (Invasive, Non-Invasive), End-Users (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of World).

Neuromodulation Devices Market Competitive Landscape
The Neuromodulation Devices market is classified as Moderately Concentrated. A group of large, diversified medical technology companies with deep neuromodulation portfolios, including Medtronic, Abbott Laboratories, Boston Scientific Corp., and LivaNova PLC, anchor the top tier through broad device-type coverage, established reimbursement relationships, and global commercial reach, while focused specialists such as Nevro Corp. compete through differentiated spinal cord stimulation technology and continued clinical evidence generation. Diversified medical technology companies including Baxter International Inc., B. Braun Melsungen AG, Smith's Medical, and Stryker participate through adjacent interventional pain, infusion, and surgical technology portfolios that support the broader chronic-pain and neurological-care ecosystem in which neuromodulation devices are used.

Which MedTech key players in the Neuromodulation Devices Market are set to emerge as the trendsetter explore @ https://www.delveinsight.com/sample-request/neuromodulation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Neuromodulation Devices Companies
Abbott Laboratories, Smith's Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC, Medtronic, Nevro Corp., and Stryker, and others.

Neuromodulation Devices Market Restraints
Despite strong momentum, the Neuromodulation Devices market faces material constraints. Implantable neuromodulation systems and their associated surgical procedures carry high upfront costs, and reimbursement policy and coverage criteria vary considerably across geographies, which can slow adoption in price-sensitive and emerging markets. The invasive nature of many devices carries inherent surgical risks, including infection, lead migration, and hardware-related complications, while battery longevity, MRI-compatibility limitations, and the need for periodic device replacement add to long-term cost of care. A shortage of physicians trained in device implantation and programming constrains scale-up in several regions, and stringent regulatory pathways for implantable Class III devices lengthen development and approval timelines.

Interested in knowing the Neuromodulation Devices Market by 2034? Click to get a snapshot of the Neuromodulation Devices Market Trends- https://www.delveinsight.com/sample-request/neuromodulation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Neuromodulation Devices Market Report
• Coverage- Global
• Forecast Period- 2026-2034
• Neuromodulation Devices Companies- Abbott Laboratories, Smith's Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC, Medtronic, Nevro Corp., and Stryker, and others.
• Neuromodulation Devices Market Restraints and Regulatory Analysis
• Neuromodulation Devices Porter Five Forces Analysis and Market Assessment

Explore more information of the Neuromodulation Devices Market Insights @ https://www.delveinsight.com/sample-request/neuromodulation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Neuromodulation Devices Market Report Introduction
2. Neuromodulation Devices Market Executive Summary
3. Neuromodulation Devices Competitive Landscape
4. Neuromodulation Devices Regulatory Analysis
5. Neuromodulation Devices Market Key Factors Analysis
6. Neuromodulation Devices Market Porter's Five Forces Analysis
7. Neuromodulation Devices Market Assessment
8. Neuromodulation Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.